More Alberta seniors are now eligible for provincially funded RSV vaccines. All Albertans 70 and over are now eligible.

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products ...

Blue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium Blue Lake Biotechnology, Inc., a clinical-stage ...

A study found that around 4 months after vaccination, people who received the RSV vaccine had a 79% reduction in their risk of getting lower ...

In an era where misinformation can spread rapidly online, parents are often left grappling with conflicting advice about their children's health.

Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

Robust immune responses were observed among healthy and high-risk younger adults who received the Ad26/protein RSV preF vaccine.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an mRNA respiratory syncytial virus (RSV) ...

Here are four more updates: Influenza activity remained elevated but has been declining for four consecutive weeks. Flu-related emergency department visits remain moderate, and test positivity is at ...

As global capital flows positively into the pharmaceutical sector, PRC vaccine leader AIM Vaccine announced on February 26 that its self-developed mRNA RSV vaccine has recently received clinical trial ...

Participants were observed for two seasons, from August 31, 2021, to December 18, 2023, to evaluate vaccine efficacy, its safety and the increase in antibody levels against RSV-A and RSV-B variants.